CMV complications in common variable immunodeficiency.
A patient suffering from common variable immunodeficiency is described, who developed a myelitis under treatment with glucocorticosteroids. Later on, autoimmune complications had to be treated with azathioprine. An exacerbation of the myelitis, retinitis, encephalitis and colitis was observed and a cytomegalovirus infection diagnosed. This infection does not represent a typical complication of common variable immunodeficiency. A functional NK cell defect was detected that may contribute to susceptibility for cytomegalovirus infection in addition to immunosuppressive therapy.
Witte
T
T
Abteilung Klinische Immunologie, Medizinische Hochschule Hannover, Germany. witte.torsten@mh.hannover.de
Werwitzke
S
S
Schmidt
R E
RE
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D000077404:Cidofovir; D003092:Colitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D017074:Common Variable Immunodeficiency / Q000150:complications / Q000276:immunology* / Q000503:physiopathology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D018792:Encephalitis, Viral / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use; D006801:Humans; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000276:immunology; D009187:Myelitis / Q000150:complications / Q000276:immunology / Q000503:physiopathology; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010750:Phosphoproteins / Q000032:analysis; D014763:Viral Matrix Proteins / Q000032:analysis
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D001379:Azathioprine